1-hydroxy-2-ethoxycarbonyl-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene | 172937-63-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-hydroxy-2-ethoxycarbonyl-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene
• 英文别名: ethyl 5-[tert-butyl(diphenyl)silyl]oxy-1-hydroxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
• CAS: 172937-63-2
• 化学式: C₂₉H₃₄O₄Si
• 分子量: 474.672
• InChiKey: ALQVNNJMUHXXMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.78
• 重原子数：
  34
• 可旋转键数：
  8
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.34
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-hydroxy-2-ethoxycarbonyl-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene 在 吡啶 、 potassium hydrogensulfate 、 四丁基氟化铵 、 二异丁基氢化铝 、 potassium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 2-(N,N-diphenylcarbamoyloxymethyl)-5-ethoxycarbonylmethyloxy-3,4-dihydronaphthalene
  参考文献：
  名称：

  Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3

  摘要：

  The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K-i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.047
• 作为产物：
  描述：

  5-t-butyldiphenylsilyloxy-2-ethoxycarbonyl-1-oxo-1,2,3,4-tetrahydronaphthalene 在 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 1-hydroxy-2-ethoxycarbonyl-5-t-butyldiphenylsilyloxy-1,2,3,4-tetrahydronaphthalene
  参考文献：
  名称：

  Naphthalene derivatives as prostaglandin I.sub.2 agonsists

  摘要：

  一种化学式为##STR1##的化合物，其中R.sup.1是羧基或保护的羧基，R.sup.2是氢、羟基或保护的羟基，R.sup.3是氢、羟基、保护的羟基等，R.sup.4是氢或卤素，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，--R.sup.5是##STR2##（其中R.sup.6是单（或双或三）芳基（较低）烷基，Z为N或CH），等等，以及##STR3##和其药用盐，可用作药物。

  公开号：

  US05763489A1

文献信息

• Naphthalene derivatives as prostaglandin I.sub.2 agonsists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05763489A1

  公开（公告）日：1998-06-09

  A compound of the formula ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is hydrogen, hydroxy, protected hydroxy, etc., R.sup.4 is hydrogen or halogen, A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene, --R.sup.5 is ##STR2## (in which R.sup.6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc., and ##STR3## and a pharmaceutically acceptable salt thereof which are useful as medicaments.

  一种化学式为##STR1##的化合物，其中R.sup.1是羧基或保护的羧基，R.sup.2是氢、羟基或保护的羟基，R.sup.3是氢、羟基、保护的羟基等，R.sup.4是氢或卤素，A.sup.1是较低的烷基，A.sup.2是键或较低的烷基，--R.sup.5是##STR2##（其中R.sup.6是单（或双或三）芳基（较低）烷基，Z为N或CH），等等，以及##STR3##和其药用盐，可用作药物。
• Naphthalene derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05863918A1

  公开（公告）日：1999-01-26

  A compound or the formula: ##STR1## wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is hydrogen, hydroxy or protected hydroxy, R.sup.3 is hydrogen, hydroxy, protected hydroxy, etc., R.sup.4 is hydrogen or halogen, A.sup.1 is lower alkylene, A.sup.2 is bond or lower alkylene, --R.sup.5 is ##STR2## (in which R.sup.6 is mono(or di or tri)aryl(lower)alkyl and Z is N or CH), etc., and ##STR3## etc., and a pharmaceutically acceptable salt thereof which are useful as medicaments.

  一种化合物或式子：##STR1## 其中R.sup.1是羧基或保护羧基，R.sup.2是氢，羟基或保护羟基，R.sup.3是氢，羟基，保护羟基等，R.sup.4是氢或卤素，A.sup.1是低级烷基，A.sup.2是键或低级烷基，--R.sup.5是##STR2## （其中R.sup.6是单（或二或三）芳基（低）烷基，Z是N或CH），等等，以及其药学上可接受的盐，可用作药物。
• Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: Orally active prostacyclin mimetics. Part 3
  作者：Kouji Hattori、Akira Tanaka、Osamu Okitsu、Seiichiro Tabuchi、Kiyoshi Taniguchi、Mie Nishio、Satoshi Koyama、Masahide Higaki、Jiro Seki、Kazuo Sakane

  DOI：10.1016/j.bmcl.2005.04.047

  日期：2005.6

  The new classes of diphenylcarbamate derivatives with a tetrahydronaphthalene skeleton as highly potent and selective IP agonists have been discovered. The optimized diphenylcarbamate type compound FK-788: (R)-4 exhibited potent antiaggregative potency with an IC50 of 18 nM and high binding affinity for the human recombinant IP receptor with K-i values of 20 nM and selectivity for human IP over all other members of the human prostanoid receptor family. Compound (R)-4 was shown to exhibit good pharmacokinetic properties in rats and dogs, and also good bioavailability in healthy volunteers. (c) 2005 Elsevier Ltd. All rights reserved.